Digitisation | August 10, 2021
Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
It had an estimated market size of US $ 32 million as of June 2021
Five seats reserved for Wards of COVID warriors in central MBBS admission
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Complementary business models are the reason for the acquisition
Subscribe To Our Newsletter & Stay Updated
